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Abstract
Background: Although metabolomic approaches have begun to document numerous changes that arise in end
stage renal disease (ESRD), how these alterations relate to established metabolic phenotypes in uremia is unknown.
Methods: In 200 incident hemodialysis patients we used partial least squares discriminant analysis to identify which
among 166 metabolites could best discriminate individuals with or without diabetes, and across tertiles of body
mass index, serum albumin, total cholesterol, and systolic blood pressure.
Results: Our data do not recapitulate metabolomic signatures of diabetes and obesity identified among individuals
with normal renal function (e.g. elevations in branched chain and aromatic amino acids) and highlight several
potential markers of diabetes status specific to ESRD, including xanthosine-5-phosphate and vanillylmandelic acid.
Further, our data identify significant associations between elevated tryptophan and long-chain acylcarnitine levels
and both decreased total cholesterol and systolic blood pressure in ESRD. Higher tryptophan levels were also
associated with higher serum albumin levels, but this may reflect tryptophan’s significant albumin binding. Finally,
an examination of the uremic retention solutes captured by our platform in relation to 24 clinical phenotypes
provides a framework for investigating mechanisms of uremic toxicity.
Conclusions: In sum, these studies leveraging metabolomic and metabolic phenotype data acquired in a
well-characterized ESRD cohort demonstrate striking differences from metabolomics studies in the general
population, and may provide clues to novel functional pathways in the ESRD population.
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Background
End stage renal disease (ESRD) is characterized by various
metabolic disturbances linked to adverse outcomes, but
the nature of these associations is poorly understood or
even counterintuitive [1]. For example, low serum albumin
has consistently been linked to cardiovascular mortality in
dialysis [2, 3], yet the association is not simply a result of
inadequate nutrition, as intradialytic parenteral nutrition
does not always improve survival in malnourished ESRD
patients [4], and alternative pathways including inflam-
mation are known to contribute [5]. Dyslipidemia is
also common in ESRD, including atherogenic increases
in carbamylated and oxidized-LDL cholesterol. Clinical
trials, however, have failed to demonstrate a survival
benefit with statin therapy in ESRD, despite substantial
reductions in LDL cholesterol [6, 7]. Indeed, several
studies have identified an inverse association between
cholesterol levels and uremic cardiovascular risk [8, 9].
Similar paradoxical associations, sometimes described
as examples of ‘reverse epidemiology’ in ESRD, have
been noted with body mass index (BMI) and blood
pressure [8, 10–12] and survival on hemodialysis.
Metabolomic approaches enable high resolution inter-
rogation of metabolic phenotypes. For example, studies
have begun to highlight specific metabolites associated
with obesity and diabetes risk in the general population,
particularly branched-chain and aromatic amino acids,
but also short chain acylcarnitines, the glutamate/glu-
tamine ratio, and bile acids [13–23]. Ultimately, these
findings may lead to a more refined understanding of
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underlying disease mechanisms. Whether these and other
associations identified in the burgeoning metabolomics
literature extend to the ESRD population is unknown.
While initial applications of metabolomics to nephrology
research have generated a broad view of uremia [24] and
the immediate effects of the hemodialysis procedure
[25, 26], no studies have explicitly examined the cross-
sectional relationship between uremic metabolite
alterations and metabolic or other clinical phenotypes
captured in a given ESRD study population.
We recently performed liquid chromatography-mass
spectrometry (LC-MS) based metabolite profiling on
plasma obtained from incident hemodialysis subjects in the
Accelerated Mortality on Renal Replacement (ArMORR)
cohort, and highlighted baseline levels of long-chain acyl-
carnitines as markers of future cardiovascular death in a
longitudinal study [27]. Using this data set, we now lever-
age the rich clinical phenotyping available in ArMORR to
examine cross-sectional associations between plasma me-
tabolite levels and select metabolic phenotypes. Specifically,
we sought to identify associations between metabolites and
metabolic phenotype data in this well-characterized ESRD
cohort, hypothesizing that these findings would differ from
metabolomic associations derived from the general popula-
tion. The aim of such work is to gain new insights into the
functional metabolic pathways that underlie the poorly
understood associations between clinical outcomes in
ESRD and variables such as BMI, albumin, cholesterol, and
blood pressure. Further, we examined the correlation be-
tween the subset of metabolites measured by our platform
that are known uremic retention solutes and numerous
clinical variables captured in ArMORR. Taken together,
these results provide a new perspective on the metabolic
disturbances that accompany and arise in ESRD.
Methods
Study population
The Accelerated Mortality on Renal Replacement
(ArMORR) study is a prospective cohort study of 10,044
incident hemodialysis patients in any of 1,056 U.S. centers
operated by Fresenius Medical Care North America be-
tween June 2004 and August 2005. Full details have been
previously published [27–31]. All subjects underwent
1 year of follow-up except for those who died (15.2 %),
voluntarily discontinued dialysis (5 %), underwent kidney
transplantation (3 %), recovered renal function (4 %), or
transferred to a dialysis unit outside the Fresenius system
(12 %). Clinical data were prospectively collected by physi-
cians at the point-of-care and included demographics,
coexisting conditions, and routine laboratory studies.
Plasma samples drawn at the beginning of a dialysis
session within 14 days of initiation of outpatient
hemodialysis, and that would otherwise have been dis-
carded after routine clinical testing, were saved and stored
in liquid nitrogen. We previously evaluated the associa-
tions between metabolite profile and mortality in the
ArMORR cohort in a study of 100 randomly selected
patients who died within the first year of dialysis from a
cardiovascular cause, and 100 patients who were alive
1 year after starting dialysis, frequency matched for age,
sex, and race [27]. We included this entire group of indi-
viduals in the current study. This study was approved by
the Massachusetts General Hospital IRB, which waived
the need for informed consent because all personal identi-
fiers were removed from the blood samples and clinical
data before transfer to the investigators.
Metabolite profiling
We applied two distinct LC-MS based methods to distinct
plasma aliquots for each study subject. Amino acids,
amino acid derivatives, urea cycle intermediates, nucleo-
tides and other positively charged polar metabolites were
profiled as previously described [14]. Briefly, 10 μL of
plasma were extracted with 90 μL of 74.9:24.9:0.2 vol/vol/
vol acetonitrile/methanol/formic acid containing valine-d8
(Sigma-Aldrich; St Louis, MO). After centrifugation, su-
pernatants underwent hydrophobic interaction chroma-
tography using a 150 × 2.1 mm Atlantis hydrophobic
interaction chromatography column (Waters, Milford,
MA), and MS data were acquired on a 4000 QTRAP triple
quadrupole mass spectrometer (AB SCIEX, Foster City,
CA) using ESI and MRM in the positive ion mode.
Organic acids, sugars, bile acids, and other negatively
charged polar metabolites were profiled as previously de-
scribed [32]. Briefly, 30 μL of plasma were extracted with
the addition of four volumes of 80:20 vol/vol methanol/
water containing isotope-labeled inosine-15 N4, superna-
tants underwent chromatography on a 150 × 2.0 mm
Luna NH2 column (Phenomenex; Torrance, CA), and MS
data were acquired using a 5500 QTRAP triple quadru-
pole mass spectrometer (AB SCIEX; Foster City, CA)
using ESI and MRM in the negative ion mode.
Statistical analyses
We first examined the association between plasma metab-
olites and pre-selected metabolic phenotypes: diabetes sta-
tus, BMI, serum albumin, total cholesterol, and systolic
blood pressure (SBP). We focused on these phenotypes
because of their strong links to metabolism and their
established, but incompletely understood, associations
with ESRD mortality [33–39]. To investigate differences in
metabolite profiles across these phenotypes, continuous
outcomes measures (BMI, albumin, total cholesterol, and
SBP) were divided into tertiles. Diabetes status was classi-
fied as “yes” or “no”.
Because of the number of metabolites measured by our
LC-MS platform (166 total, Additional file 1: Table S1),
many with significant inter-correlations, we performed
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partial least squares discriminant analysis (PLS-DA) to
visualize the linear components that discriminate individ-
uals across the categories (tertiles or class) of metabolic
phenotypes. PLS-DA was performed on log transformed
and auto-scaled (mean-centered and divided by the stand-
ard deviation of each metabolite) data using MetaboAnalyst
2.0 [40, 41]. This program performs PLS regression using
the plsr function provided by the pls package in R, and
classification and cross validation using the corresponding
wrapper function offered by the caret package. Variable
Importance in Projection (VIP) scores generated by this
program estimate the importance of each variable in the
projection used within the PLS model. A variable with a
VIP score greater than 1 can be considered important in a
given model. The metabolites with the highest VIP scores
were further analyzed by comparing their levels across
classes using Mann-U-Whitney and Kruskal-Wallis tests
as appropriate.
Finally, heatmaps were created to represent Pearson cor-
relation (r) and P-value matrices between available clinical
variables in the cohort and the subset of metabolites mea-
sured by our platform that have previously been described
as uremic retention solutes (http://www.uremic-toxins.org)
[27, 42–45].
To account for multiple testing, we used a Bonferroni
corrected significance threshold of P < 0.0003 (0.05/166)
for comparisons of individual metabolites across pheno-
type class. For the correlation matrices, we used an
adjusted significance threshold of P < 0.00007 (0.05/[29
metabolites* 24 clinical variables]). A sensitivity analysis
was performed to gauge the influence of case–control sta-
tus (i.e. whether or not a given individual died of a cardio-
vascular cause within one year of starting dialysis) on the
associations described herein. Stratified analysis by case
status did not alter the statistical significance of the
models described. Therefore, we did not stratify models
by mortality status and analyzed the entire group of 200
individuals together as a cohort. All analyses were per-
formed using SAS software version 9.1.3 (SAS Institute)
and MetaboAnalyst 2.0 software (www.metaboanalyst.ca).
Results and discussion
Cohort characteristics
As shown in Table 1, the mean age of the study popula-
tion was 69.5 years and 69 % of subjects were white. There
was an equal representation of males and females and
nearly half of the individuals had a history of diabetes or
had diabetes listed as their cause of ESRD (49 %). The
mean BMI was 26.5 kg/m2 (SD ±7.6 kg/m2) and the mean
SBP was 144 mmHg (±27 mmHg). A minority of individ-
uals reported a lipid disorder (12 %) and the median total
cholesterol level was 162 mg/dL (quartile1-quartile3,
127–188 mg/dL). The median serum albumin level was
3.6 g/dl (3.2-3.8 g/dL).
Examination of metabolite profiles and select metabolic
phenotypes
The PLS-DA approach allowed us to visualize and extract
the metabolites that best separated individuals (Figs. 1,2,3,4
Table 1 Baseline characteristics of the study sample
Variable Total n = 200
Age, years 69.5 ± 13.6
Male 53 % (106)
Race
White 69 % (138)
Black 24 % (48)
Other 7 % (14)
Coexisting conditions
Coronary artery disease 18 % (36)
Lipid disorders 12 % (23)
Congestive heart failure 18 % (35)
Cause of end-stage renal disease
Diabetesa 49 % (97)
Hypertensive renal disease 38 % (75)
Glomerulonephropathy 4 % (7)
Vascular access
Fistula 24 % (47)
Graft 13 % (25)
Catheter 59 % (118)
Body Mass Index (kg/m2) 26.5 ± 7.6
Systolic blood pressure (mmHg) 144.4 ± 27.3
Diastolic blood pressure (mmHg) 72.5 ± 18.6
Urea reduction ratio 68.6 ± 10.3
Laboratory data
N-terminal pro-BNP (ng/L) 8029 (3,757 – 21,404)
Troponin T (μg/L) 0.14 (0.04 – 0.13)
Total cholesterol (mg/dL) 162 (127 – 188)
LDL (mg/dL) 83 (63 – 103)
HDL (mg/dL) 41 (32 – 47)
Triglycerides (mg/dL) 157 (93 – 199)
Creatinine (mg/dL) 5.7 (4.0 – 7.0)
White blood cell (109/L) 8.3 (6.2 – 9.8)
Hemoglobin (g/dL) 10.4 (9.5 – 11.2)
Albumin (g/dL) 3.5 (3.2 – 3.8)
Ferritin (ng/mL) 285.7 (81.5 – 346.0)
Transferrin saturation (%) 20.2 (13.0 – 24.0)
Phosphorus (mg/dL) 4.5 (3.4 – 5.4)
Parathyroid hormone (pg/mL) 268.6 (124.0 – 235.0)
Categorical data are percentages (counts). Counts may not equal total n due
to missing data. Clinical measures are means ± SD. Laboratory values are
median (quartile 1 – quartile 3)
BNP, brain natriuretic peptide
aIncludes all patients with diabetes
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Fig. 1 Comparison of metabolite profiles and diabetes status. Study subjects were grouped by diabetes status (yes/no). Left: Partial least squares
discriminant analysis (PLS-DA) score plot for the study population separated by phenotype class. Oval outlines denote 95 % confidence intervals.
Right: The variable importance in projection (VIP) scores for the 15 metabolites with the greatest score. The colored boxes on the right indicate
the direction of metabolite alterations across phenotype class. Abbreviations: XMP, Xanthosine-5-phosphate; VMA, vanillylmandelic acid; 3-PG,
3-phosphoglycerate; mevalonate-5P, mevalonate-5-phosphate; PEP, phosphoenolpyruvate; ribose-5P, ribose-5-phosphate and ribulose-5-phosphate
Fig. 2 Comparison of metabolite profiles across tertile of body mass index (BMI). Study subjects were grouped by BMI tertile (tertile 1 = lowest
BMI). Left: Partial least squares discriminant analysis (PLS-DA) score plot for the study population separated by phenotype class. Oval outlines
denote 95 % confidence intervals. Right: The variable importance in projection (VIP) scores for the 15 metabolites with the greatest score.
The colored boxes on the right indicate the direction of metabolite alterations across phenotype tertile. Abbreviations: BAIBA, β-aminoisobutyric
acid; SDMA, symmetric dimethylarginine; 3-PG, 3-phosphoglycerate; b-OH-butyrate, β-hydroxybutryate; p-creatine, phosphocreatine;
XMP, Xanthosine-5-phosphate
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Fig. 3 Comparison of metabolite profiles across tertile of serum albumin. Study subjects were grouped by albumin tertile (tertile 1 = lowest). Left:
Partial least squares discriminant analysis (PLS-DA) score plot for the study population separated by phenotype class. Oval outlines denote 95 %
confidence intervals. Right: The variable importance in projection (VIP) scores for the 15 metabolites with the greatest score. The colored boxes
on the right indicate the direction of metabolite alterations across phenotype tertile. Abbreviations: BAIBA, β-aminoisobutyric acid; SDMA, symmetric
dimethylarginine; GCDCAs, glycodeoxycholate and glycochenodeoxycholate; ADP, adenosine diphosphate
Fig. 4 Comparison of metabolite profiles across tertile of total cholesterol. Study subjects were grouped by cholesterol tertile (tertile 1 = lowest).
Left: Partial least squares discriminant analysis (PLS-DA) score plot for the study population separated by phenotype class. Oval outlines denote
95 % confidence intervals. Right: The variable importance in projection (VIP) scores for the 15 metabolites with the greatest score. The colored
boxes on the right indicate the direction of metabolite alterations across phenotype tertile. Abbreviations: GMP, guanosine monophosphate;
AMP, adenosine monophosphate; p-creatine, phosphocreatine
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and 5; left panels) across phenotype tertile or class
(Table 2). Because four of the clinical phenotypes we stud-
ied (BMI, serum albumin, total cholesterol, and SBP) are
continuous measures, we recognize that tertile cut-offs do
not demarcate distinct physiologic or pathophysiologic
processes. Thus, plot overlap across tertiles was expected.
Variable importance in projection (VIP) provided a score
for each metabolite, ranking the metabolites according to
their predictive power in the PLS model; the fifteen metab-
olites with the highest VIP scores for each plot are shown
in Figs. 1, 2, 3, 4 and 5 (right panels), and the levels of these
metabolites across tertiles (or class) of the phenotypes with
corresponding test statistics are shown in Tables 3-7.Values
are median peak area for the metabolites (quartile 1, quar-
tile 3)*P-value significant at the Bonferroni adjusted level
of 3.0 × 10−4
For individuals with or without diabetes, glucose was one
of the strongest discriminating metabolites, with higher
levels among the individuals with diabetes (Fig. 1).
Xanthosine-5-phosphate (XMP) and vanillylmandelic acid
(VMA), however, had even higher VIP scores than glucose,
with XMP levels higher and VMA levels lower among the
individuals with diabetes (P = 5.0 × 10−7 and 1.5 × 10−6 for
XMP and VMA, respectively). Other significant differences
included higher levels of 3-phosphoglyceric acid (P = 4.9 ×
10−5), methionine (P = 4.5× 10−5), mevalonate-5-phosphate
(P = 2.8 × 10−4), and ornithine (P = 3.2 × 10−4) among
individuals with diabetes. Tyrosine, an aromatic amino
acid, had a nominal association with diabetes status
(P = 1.0 × 10−3). There were no significant associations
between tyrosine levels, or any aromatic or branched-
chain amino acid levels, with BMI (Table 4). In fact,
none of these metabolites had even a nominal association
with BMI in univariate comparisons (data not shown).
Overall, the ability of metabolite profiles to discriminate
individuals across tertiles of BMI was poor (Fig. 2). Among
the top metabolites by VIP score, only 20:4 carnitine (ara-
chidonyl carnitine), β-hydroxybutyrate, and benzoate had
nominal P-values in univariate analysis (Table 4).Values are
median peak area for the metabolites (quartile 1, quartile
3)*P-value significant at the Bonferroni adjusted level of
3.0 × 10−4Values are median peak area for the metabolites
(quartile 1, quartile 3)*P-value significant at the Bonferroni
adjusted level of 3.0 × 10−4
Thus, our data from an ESRD population do not recap-
itulate observations derived in the general population link-
ing diabetes and obesity with elevations in branched chain
and aromatic amino acids (except for the nominal associ-
ation with tyrosine noted above), short chain acylcarni-
tines, the glutamate/glutamine ratio, or bile acids [2]. One
potential explanation is that kidney function (and dys-
function) has a direct effect on select metabolites. The
interaction between kidney function and amino acid
metabolism, in particular, has been closely examined. For
example, the kidney is known to make a substantial
contribution to whole body tyrosine appearance via intra-
Fig. 5 Comparison of metabolite profiles across tertile of systolic blood pressure. Study subjects were grouped by systolic blood pressure tertile
(tertile 1 = lowest). Left: Partial least squares discriminant analysis (PLS-DA) score plot for the study population separated by phenotype class.
Oval outlines denote 95 % confidence intervals. Right: The variable importance in projection (VIP) scores for the 15 metabolites with the
greatest score. The colored boxes on the right indicate the direction of metabolite alterations across phenotype tertile. Abbreviations: ADMA,
asymmetric dimethylarginine
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organ phenylalanine hydroxylation [46]. Further, the
metabolic acidosis that results from renal failure leads to
increased leucine oxidation [47], and indeed, generalized
muscle catabolism. The significant associations we did
identify with diabetes status in ESRD, e.g. XMP (a purine
breakdown product) and VMA (a catecholamine metabol-
ite), have not been reported in the general population. To
what extent these alterations reflect distinct pathophysio-
logic processes in uremia warrant further investigation.
For individuals in different tertiles of serum albumin,
PLS-DA demonstrated moderate separation across groups
(Fig. 3). Tryptophan and its downstream metabolite
kynurenine were significantly higher in individuals with
higher serum albumin levels (P = 1.8 × 10−4 and 2.5 × 10−4,
respectively). Two additional tryptophan metabolites,
indoxyl sulfate and indole lactate, had a trend for higher
levels among individuals with higher serum albumin
levels. Given recent observations that ascribe a functional
role for tryptophan metabolism, specifically through
indoleamine-2, 3-dioxygenase (IDO), in modulating the
immune system and vascular tone [48, 49], it is an
appealing link between metabolism, nutritional status,
inflammation, and cardiovascular risk in ESRD. How-
ever, these data should be interpreted with caution.
Because tryptophan and its catabolites are hydrophobic,
their positive correlation with albumin may reflect their
significant protein-binding [50] – our LC-MS method
measures total, not free, plasma metabolite levels. A
similar mechanism may underlie the trend for associ-
ation between thyroxine and albumin levels. By con-
trast, creatine, the metabolite with the third highest
VIP score, had a trend for higher levels among individ-
uals with lower serum albumin levels. In a study that
examined spent media from cultured muscle cells
treated with mitochondrial respiratory chain inhibitors,
as well as plasma obtained from individuals with
respiratory chain diseases, creatine levels were reprodu-
cibly elevated [51]. In cell culture, extracellular creatine
was inversely correlated with the intracellular phospho-
creatine/creatine ratio, suggesting that elevated plasma
creatine may signal a low energetic state in tissues
using the creatine phosphate shuttle. Interestingly, ele-
vated plasma creatine and decreased plasma phospho-
creatine levels both have a nominal association with
Table 2 Primary metabolic phenotypes by tertiles
Tertile Measure
Body mass index (kg/m2) 1 20.2 ± 3.9
2 25.6 ± 1.3
3 34.2 ± 7.6
Albumin (g/dl) 1 3.1 (2.8, 3.2)
2 3.6 (3.4, 3.7)
3 4.0 (3.8, 4.2)
Cholesterol (mg/dl) 1 116.0 (106.0-126.0)
2 154.0 (146.0-163.0)
3 209.5 (188.0-236.0)
Systolic blood pressure (mmHg) 1 116.1 ± 10.0
2 142.2 ± 7.0
3 174.6 ± 20.2
Clinical measures are mean ± SD and laboratory values are median
(quartile 1 to quartile 3)
Total n = 200
Table 3 Cross sectional analysis of diabetes status and select metabolites
no DM DM P
XMP 13 585 (8 386, 29 579) 62 101 (14 261, 158 938) 5.0E-7*
VMA 173 153 (107 165, 279 690) 104 186 (67 902, 164 683) 1.5E-6*
Glucose 2 935 (1 046, 5 294) 6 245 (2 777, 9 807) 3.1E-6*
3-PG 2 475 150 (1 882 036, 333 2264) 3 767 372 (2 250 378, 5 598 373) 4.9E-5*
Methionine 195 026 (152 633, 239 841) 243 230 (195 219, 283 910) 4.5E-5*
Adenosine 1 942 (1 463, 3 457) 3 078 (1 706, 5 137) 8.6E-4
mevalonate-5P 192 139 (136 927, 291 930) 292 904 (165 128, 433 871) 2.8E-4*
ornithine 1 385 224 (1 083 311, 1 721 772) 1 657 626 (1 351 270, 1 913 549) 3.2E-4*
uracil 6 888 567 (4 490 348, 9 622 913) 4 784 283 (3 740 917, 6 592 407) 5.7E-4
lactose 3 140 699 (2 178 153, 4 835 219) 4 519 336 (2 900 447, 6 650 384) 3.8E-4
xanthosine 10 839 (7 518, 22 311) 22 007 (8 845, 36 474) 1.0E-3
tyrosine 222 479 (174 354, 277 562) 247 875 (210 621, 309 004) 2.2E-3
serine 352 671 (280 146, 415 607) 381 134 (319 491, 476 035) 4.6E-3
PEP 312 003 (189 719, 522 172) 462 016 (257 705, 925 860) 1.3E-3
ribose-5-P-rib 144 443 (104 797, 208 719) 180 078 (116 088, 322 799) 8.7E-3
Values are median peak area for the metabolites (quartile 1, quartile 3)
*P-value significant at the Bonferroni adjusted level of 3.0 × 10−4
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increased 1-year cardiovascular mortality among inci-
dent dialysis patients in ArMORR [27]. These observa-
tions raise the possibility that impaired mitochondrial
respiration in muscle is linked to the pathogenesis of
hypoalbuminemia in dialysis.
For individuals across tertiles of total cholesterol and
SBP, PLS-DA again demonstrated moderate separation
across tertiles (Figs. 4 and 5). For both analyses, long-
chain acylcarnitines were among the metabolites with the
highest VIP scores, with 18:2 carnitine (linoleylcarnitine,
P = 9.0 × 10−7), 18:1 carnitine (oleoylcarnitine, P = 6.0 ×
10−7), and 18:0 carnitine (stearoylcarnitine, P = 7.7 × 10
−5) all significantly higher in individuals with lower total
cholesterol levels (Table 6,) and linoleylcarnitine (P =
5.5 × 10−5) and oleoylcarnitine (P = 8.7 × 10−6) signifi-
cantly higher in individuals with lower SBP (Table 7); se-
lect short-chain and medium-chain acylcarnitines were
also significantly elevated among individuals with lower
SBP. Like albumin, low cholesterol and blood pressure
are established predictors of increased mortality in ESRD
Table 4 Cross sectional analysis of BMI tertiles and select metabolites
1 2 3 P
20:4 carnitine 296 (246, 378) 263 (216, 324) 253 (207, 292) 7.8E-3
b-OH-butyrate 508 950 (249 015, 1 818 943) 395 440 (234 716, 895 354) 343 616 (172 233, 717 989) 2.9E-2
benzoate 15 216 (11 526, 24 891) 18 382 (12 187, 28 788) 21 271 (14 892, 34 600) 4.1E-2
9:0 carnitine 17 878 (11 801, 23 836) 16 514 (9 560, 24 702) 13 239 (9 472, 20 371) 5.7E-2
BAIBA 49654 (26452, 107799) 36205 (24704, 57849) 38844 (23864, 74057) 1.3E-1
SDMA 942527 (769351, 1098799) 852551 (750082, 970184) 826704 (729114, 1062038) 7.4E-2
niacinamide 209151 (170065, 248736) 214718 (175857, 281191) 246744 (187545, 297341) 6.8E-2
p-creatine 42402 (31941, 51249) 47705 (39559, 61036) 48786 (37472, 57166) 4.0E-2
succinate 17 776 284 (15 961 017, 22 206 915) 15 637 602 (12 262 309, 19 434 811) 16 309 449 (12 852 577, 19 680 091) 6.1E-3
putrescine 68559 (44891, 109979) 54285 (18371, 87225) 53 504 (12105, 93032) 1.3E-1
XMP 21 819 (11 029, 53 381) 20 694 (8 856, 143 900) 37 771 (12 370, 121 441) 1.7E-1
adenine 90 351 (61 426, 165 720) 109 819 (79 107, 201 534) 116 489 (76 249, 194 627) 1.1E-1
glutamate 870 295 (691 881, 1 109 208) 992 968 (715 437, 1 375 593) 1 031 076 (714 204, 1 443 438) 1.2E-1
3-PG 2 824 102 (1 855 508, 4 336 931) 2 788 537 (1 930 889, 5 190 633) 3 294 065 (2 358 954, 5 383 792) 9.2E-2
xanthosine 12 923 (7 425, 24 088) 10 883 (7 604, 33 249) 19 991 (8 413, 30 597) 1.7E-1
Values are median peak area for the metabolites (quartile 1, quartile 3)
*P-value significant at the Bonferroni adjusted level of 3.0 × 10−4
Table 5 Cross sectional analysis of albumin tertiles and select metabolites
1 2 3 P
kynurenine 425 998 (298 054, 535 460) 478 927 (395 468, 596 735) 552 251 (433 248, 679 481) 1.8E-4*
tryptophan 273 066 (223 467, 413 194) 315 338 (255 914, 423 927) 393 551 (301 885, 501 066) 2.5E-4*
creatine 2 157 292 (1 397 576, 3 355 087) 1 907 461 (1 145 455, 2 791 140) 1 570 693 (1 182 023, 2 037 120) 4.9E-3
indoxylsulfate 42 510 713 (24 175 943, 58 375 318) 55 564 881 (34 527 474, 67 400 369) 57 398 073 (33 359 446, 80 148 935) 1.3E-2
12:0 carnitine 28 261 (18 195, 40 622) 30 496 (18 540, 44 940) 36 915 (24 245, 50 553) 2.7E-2
aspartate 36 448 (25 083, 49 840) 34 626 (24 685, 48 518) 26 533 (20 120, 36 067) 1.9E-3
thyroxine 2 332 (1 929, 2 738) 2 523 (1 879, 2 916) 2 712 (2 115, 3 244) 1.8E-2
indolelactate 12 722 (8 573, 19 334) 15 627 (11 171, 22 311) 16 269 (11 922, 22 700) 3.6E-2
BAIBA 46 979 (27 423, 106 593) 42 313 (24 146, 80 713) 34 051 (23 583, 57 272) 1.0E-1
alanine 1 280 822 (985 715, 1 604 978) 1 249 845 (1 028 428, 1 494 869) 1 337 859 (1 117 636, 1 758 661) 6.9E-2
10:0 carnitine 33 566 (21 210, 61 857) 48 413 (25 775, 68 324) 47 884 (31 469, 72 628) 5.8E-2
SDMA 896 522 (765 176, 1 090 288) 925 219 (772 578, 1 063 241) 824 248 (730 601, 974 498) 5.2E-2
hydroxyproline 235 578 (162 155, 374 510) 203 966 (149 720, 306 721) 198 496 (150 564, 259 207) 1.5E-1
GCDCAs 487 186 (203 751, 773 938) 421 065 (248 114, 748 019) 715 307 (356 712, 1 064 255) 1.4E-2
ADP 280 998 (155 075, 610 214) 539 330 (278 012, 877 605) 455 070 (164 681, 1 239 020) 1.2E-2
Values are median peak area for the metabolites (quartile 1, quartile 3)
*P-value significant at the Bonferroni adjusted level of 3.0 × 10−4
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[8, 9, 11, 12]. These findings are consistent with our ob-
servation that long-chain acylcarnitines are associated
with 1-year cardiovascular mortality in ESRD [27], and
motivate further interest in long-chain acylcarnitines as
markers, or even mediators, of altered lipid metabolism
and cardiovascular function in uremia. Tryptophan, one
of the strongest discriminators of albumin tertile, was
also a top hit in regards to total cholesterol and SBP, with
higher tryptophan significantly associated with lower
levels for both. Finally, higher arginine levels were
significantly associated with higher total cholesterol and
higher deoxyadenosine levels were significantly associ-
ated with lower SBP.Values are median peak area for the
metabolites (quartile 1, quartile 3)*P-value significant at
the Bonferroni adjusted level of 3.0 × 10−4
Relation of uremic solutes with twenty-four clinical
phenotypes
To examine the specificity of the long-chain acylcarnitine-
phenotype associations described above, we looked more
Table 6 Cross sectional analysis of total cholesterol tertiles and select metabolites
1 2 3 P
tryptophan 440 068 (345 130, 586637) 323192 (257580, 429806) 274624 (223120, 324798) 1.7E-9*
18:2 carnitine 60 494 (38 250, 107 981) 49 737 (27 163, 73 344) 32 084 (19 167, 53 863) 9.0E-7*
18:1 carnitine 88 418 (58 090, 144 102) 69 442 (40 568, 103 682) 47 134 (33 127, 74 763) 6.0E-7*
18:0 carnitine 12 789 (10 118, 18 240) 10 879 (7 872, 14 622) 8 466 (6 103, 12 433) 7.7E-5*
arginine 175 576 (136 362, 259 524) 187 566 (132 389, 324 585) 321 420 (216 851, 491 848) 9.6E-6*
10:0 carnitine 52 498 (28 731, 92 694) 40 556 (26 190, 67 085) 34 244 (20 094, 52 420) 7.0E-3
glycocholate 193 580 (60 425, 672 001) 105 938 (61 765, 208 013) 76 985 (42 135, 222 324) 5.6E-3
taurocholate 128 124 (30 180, 379 765) 91 894 (35 067, 188 948) 47 535 (24 706, 128 025) 1.9E-2
GMP 640 409 (341 616, 884 723) 544 860 (409 493, 969 998) 831 864 (565 936, 1 246 583) 8.9E-3
AMP 2 898 935 (2 275 762, 3 795 325) 3 153 490 (2 679 559, 4 251 281) 3 708 724 (3 046 005, 4 670 016) 1.6E-3
carnosine 23 811 (15 639, 77 524) 34 287 (14 160, 119 781) 64 617 (29 846, 195 284) 6.5E-3
aminoadipate 139 402 (119 264, 184 086) 167 760 (130 029, 210 530) 186 821 (144 705, 242 940) 3.3E-3
16:1 carnitine 68 049 (46 259, 99 787) 65 354 (35 653, 77 665) 49 527 (39 008, 71 026) 2.1E-2
14:0 carnitine 9 893 (6 819, 17 108) 8 969 (5 659, 12 834) 7 848 (5 373, 10 960) 3.1E-2
p-creatine 42 102 (30 390, 51 406) 46 713 (36 982, 55 510) 50 600 (37 472, 70 045) 1.8E-2
Values are median peak area for the metabolites (quartile 1, quartile 3)
*P-value significant at the Bonferroni adjusted level of 3.0 × 10−4
Table 7 Cross sectional analysis of systolic blood pressure tertiles and select metabolites
1 2 3 P
14:0 carnitine 10 549 (7 384, 17 510) 7 855 (6 040, 11 626) 6 824 (4 844, 9 486) 9.0E-6*
tryptophan 433 424 (297 696, 573 865) 366 630 (261 744, 444 478) 285 101 (229 380, 350 075) 1.2E-6*
18:1 carnitine 86 406 (56 919, 127 989) 70 273 (47 764, 105 108) 52 275 (32 871, 76 097) 8.7E-6*
18:2 carnitine 55 715 (35 972, 84 528) 44 392 (31 334, 69 607) 30 733 (21 812, 54 084) 5.5E-5*
3:0 carnitine 770 205 (556 166, 976 463) 604 794 (378 770, 724 282) 549 619 (381 463, 708 095) 5.4E-5*
deoxyadenosine 882 (605, 1 330) 831 (455, 1 011) 571 (441, 787) 7.5E-5*
16:1 carnitine 70 042 (50 052, 97 483) 53 904 (39 997, 77 945) 47 577 (36 257, 68 016) 4.2E-4
18:0 carnitine 12 434 (8 777, 17 403) 10 456 (7 790, 15 356) 8 806 (6 509, 12 276) 4.2E-4
carnitine 4 940 542 (4 375 772, 5 974 275) 4 311 636 (3 616 956, 4 936 736) 4 279 513 (3 743 960, 4 756 471) 2.1E-5*
12:0 carnitine 39 844 (22 621, 61 584) 33 433 (22 258, 39 850) 27 094 (17 488, 43 033) 8.5E-3
kynurenic acid 63 185 (35 805, 129 532) 86 131 (60 982, 133 796) 116 334 (67 598, 169 586) 9.4E-4
tyrosine 255 780 (216 337, 319 582) 231 195 (200 964, 273 325) 223 332 (177 881, 270 817) 8.4E-3
ADMA 309 751 (281 198, 370 574) 290 947 (261 258, 344 552) 284 594 (248 154, 328 619) 1.1E-2
taurocholate 103 888 (39 457, 284 746) 65 463 (26 657, 196 110) 59 392 (25 323, 157 090) 1.8E-2
cytidine 60 033 (36 540, 80 779) 51 105 (32 838, 73 636) 44 821 (26 784, 61 200) 2.1E-2
Values are median peak area for the metabolites (quartile 1, quartile 3)
*P-value significant at the Bonferroni adjusted level of 3.0 × 10−4
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broadly at the correlation between all of the metabolites
captured on our platform that are uremic retention sol-
utes and 24 phenotypes captured in ArMORR. Correla-
tions between previously reported uremic retention
solutes measured by our LC-MS platform, including long-
chain acylcarnitines, and a broad array of clinical pheno-
types measured in ArMORR are shown in Fig. 6 (full
results are shown in Additional file 1: Tables S2 and S3).
The correlations for glucose, as measured by the mass
spectrometer, provide an anchor for interpreting this
data – LC-MS glucose had a strong positive correlation
with glucose measured by the clinical laboratory (r = 0.80,
P <10−15), and a modest negative correlation with serum
sodium (r = −0.21, P = 7.0 × 10−3) that did not reach statis-
tical significance, but is well recognized in the clinic (i.e.
dilutional hyponatremia due to hyperglycemia). Aside
from the correlation between the two glucose measures,
the strongest correlations identified by this broader exam-
ination of uremic metabolites were indeed between long-
chain acylcarnitines and lipid traits (total and LDL
cholesterol) and blood pressure. Among lipid phenotypes,
long-chain acylcarnitines such as oleoylcarnitine were more
strongly correlated with total (r = −0.45, P = 2.6 × 10−9) and
LDL cholesterol (r = −0.43., P = 1.7 × 10−8) than with HDL
cholesterol (r = −0.15, P = 5.7 × 10−2) or triglycerides (r =
−0.27, P = 5.0 × 10−4). Similarly, oleoylcarnitine was more
strongly correlated with SBP (r=−0.38, P= 3.4 × 10−8) than
diastolic blood pressure (r=−0.25, P = 3.0 × 10−3). Long-
chain acylcarnitines were not significantly correlated with
any non-lipid or non-blood pressure phenotype.
Among the other uremic retention solutes included in our
analysis, only kynurenic and anthranilic acid (both trypto-
phan metabolites downstream of IDO) had more than one
significant correlation with a clinical variable (Fig. 6).
Kynurenic acid was significantly correlated with diastolic
blood pressure (r= 0.32, P = 5.0× 10−6), bicarbonate (r=
−0.31, P= 1.1× 10−5), and phosphorous (r= 0.38, P= 5.7×
10−8), whereas anthranilic acid was significantly correlated
Fig. 6 Relation of uremic solutes with 24 clinical phenotypes in the ArMORR cohort. Correlation coefficient (r, left) and P values (right) generated
from Pearson correlation analyses of metabolites and available clinical variables in the ArMORR cohort. Squares outlined in red on the P value
matrix represent values significant at the Bonferroni adjusted level of P < 7.4 × 10−5. Abbreviations: ADMA, asymmetric dimethylarginine; TMAO,
trimethylamine-N-oxide; SDMA, symmetric dimethylarginine; BMI, body mass index; URR, urea reduction ratio; SBP, systolic blood pressure; DBP,
diastolic blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; BNP, b-type natriuretic peptide, TSAT, transferrin saturation;
Alk Phos, alkaline phosphatase; PTH, parathyroid hormone; WBC, white blood cell
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with alkaline phosphatase (r = 0.29, P= 6.3× 10−5) and fer-
ritin (r= 0.35, P= 9.7× 10−7), a frequently used marker of in-
flammation in hemodialysis. Notably, the other metabolites
that had a nominal association with ferritin included two
other tryptophan metabolites, kynurenic acid (r= 0.16, P=
2.6× 10−2) and quinolinate (r= 0.20, P = 6.3× 10−3), and
malondialydehyde (r= 0.24, P = 9.0× 10−4), an oxidative
stress marker. These findings reinforce a potential link be-
tween the IDO pathway and uremic inflammation. Sorbitol
(r=−0.34, P= 3.4 × 10−5), cytidine (r = −0.40, P= 1.1× 10
−6), and uracil (r =−0.42, P= 1.7× 10−7) were significantly
correlated with plasma glucose; urate (r=−0.35, P= 5.2× 10
−6) and malondialdehyde (r= 0.38, P= 5.7× 10−7) were sig-
nificantly correlated with triglycerides; hippurate (r= 0.31, P
= 7.0× 10−6) and oxalate (r= 0.36, P = 1.6× 10−7) were sig-
nificantly correlated with phosphorous; and indoxyl sulfate
(r=−0.28, P= 6.8× 10−5) was significantly correlated with
bicarbonate. Indoxyl sulfate, which has been found to have
several proinflammatory effects in model systems [52], had
no correlation with ferritin (nor transferrin saturation, nor
white blood cell count), but had a trend for a negative cor-
relation with BNP (r=−0.44, P = 4.0× 10−4).
Although significant work has been devoted to under-
standing the in vitro effects of uremic retention solutes,
less is known about how many of these metabolites
relate to clinical traits in humans. Thus, in addition to
demonstrating the specificity of select long-chain acyl-
carnitine associations, our examination of uremic metab-
olites against clinical phenotypes provides a resource for
future uremic toxin research.
Limitations
Our study has several limitations. First, by examining cross-
sectional relationships between metabolite levels and various
clinical phenotypes, our study is unable to address causation.
Instead, by applying parsimonious selection procedures and
conservative adjusted significance thresholds, we seek to
highlight notable associations for future investigations. Sec-
ond, study subjects were selected in the context of a case–
control study of 1-year cardiovascular mortality, raising the
possibility of confounding by case status. However, as noted
in the Methods, the statistical significance of the findings are
not changed when analyzed stratified by case status. Never-
theless, we acknowledge that our sample is not a random se-
lection of incident dialysis patients, potentially limiting the
generalizability of our findings. Third, residual confounding
from other sources is likely to influence the associations
described, as multivariate adjustments were not pursued.
However, because the relationship between various clinical
phenotypes and metabolite levels in uremia is unknown, we
did not want to obscure novel biological associations by stat-
istical adjustment. Thus, we present these raw associations
as a framework for interpreting and appropriately adjusting
select findings in future metabolomics studies in ESRD.
Finally, our results require replication in an independent
sample, ideally selected randomly and including both inci-
dent and prevalent dialysis patients.
Conclusions
In this report, we describe the small molecule alterations
that accompany various metabolic phenotypes in ESRD.
For phenotypes like diabetes and obesity that have been
examined using metabolomics in the general population,
our data reinforce the notion that unique pathophysio-
logic processes arise at ESRD onset. Our finding that
long-chain acylcarnitines are strongly and inversely corre-
lated with cholesterol and blood pressure corroborate their
potential value as markers of cardiovascular risk in ESRD,
whereas the association of tryptophan levels across several
phenotypes is of interest given recent studies that assign a
functional role for tryptophan metabolism in inflammation
and vascular biology. Ultimately, we hope that the breadth
of the data presented herein serves as a springboard for
investigating mechanisms of uremic toxicity and identify-
ing therapeutic targets to improve the unacceptably high
morbidity and mortality attributable to ESRD.
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